JOP20200022A1 - مركبات حلقية لولبية وطرق تصنيعها واستخدامها - Google Patents

مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Info

Publication number
JOP20200022A1
JOP20200022A1 JOP/2020/0022A JOP20200022A JOP20200022A1 JO P20200022 A1 JOP20200022 A1 JO P20200022A1 JO P20200022 A JOP20200022 A JO P20200022A JO P20200022 A1 JOP20200022 A1 JO P20200022A1
Authority
JO
Jordan
Prior art keywords
making
methods
same
compounds
spirocycle
Prior art date
Application number
JOP/2020/0022A
Other languages
English (en)
Inventor
Cheryl A Grice
Olivia D Weber
Michael B Shaghafi
Daniel J Buzard
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of JOP20200022A1 publication Critical patent/JOP20200022A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOP/2020/0022A 2017-08-29 2018-08-28 مركبات حلقية لولبية وطرق تصنيعها واستخدامها JOP20200022A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29
PCT/US2018/048388 WO2019046330A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
JOP20200022A1 true JOP20200022A1 (ar) 2020-02-02

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0022A JOP20200022A1 (ar) 2017-08-29 2018-08-28 مركبات حلقية لولبية وطرق تصنيعها واستخدامها

Country Status (24)

Country Link
US (1) US11161856B2 (ar)
EP (1) EP3675848B1 (ar)
JP (1) JP7177825B2 (ar)
KR (1) KR20200046053A (ar)
CN (1) CN111032034B (ar)
AU (1) AU2018326497A1 (ar)
BR (1) BR112020003946A2 (ar)
CA (1) CA3072926A1 (ar)
CL (1) CL2020000463A1 (ar)
CO (1) CO2020001715A2 (ar)
CR (1) CR20200088A (ar)
DO (1) DOP2020000040A (ar)
EA (1) EA202090296A1 (ar)
EC (1) ECSP20013332A (ar)
ES (1) ES2914363T3 (ar)
IL (1) IL272578A (ar)
JO (1) JOP20200022A1 (ar)
MA (1) MA50045A (ar)
MX (1) MX2020002254A (ar)
PE (1) PE20200665A1 (ar)
PH (1) PH12020500371A1 (ar)
RU (1) RU2020107039A (ar)
SG (1) SG11202000984YA (ar)
WO (1) WO2019046330A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
EP3515897B1 (en) 2016-09-19 2021-08-18 H. Lundbeck A/S Piperazine carbamates as modulators of magl and/or abhd6 and their use
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
AR115092A1 (es) 2018-05-15 2020-11-25 Abide Therapeutics Inc Inhibidores de magl
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
US11702393B2 (en) 2020-04-21 2023-07-18 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
JP2024505261A (ja) 2021-01-29 2024-02-05 セディラ・セラピューティクス・インコーポレイテッド Ｃｄｋ２阻害剤およびその使用方法
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
US20230357190A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline forms of a magl inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368354A1 (en) * 2001-03-07 2003-12-10 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2008023720A1 (fr) * 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
KR20100122508A (ko) 2008-03-05 2010-11-22 타가셉트 인코포레이티드 디아자비시클로알칸의 니코틴 아세틸콜린 수용체 서브-타입 선택성 아미드
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
JP2013521290A (ja) 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP2900669B1 (en) 2012-09-25 2019-09-04 F.Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
CA2917050A1 (en) * 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EP3328849B9 (en) 2015-07-31 2021-01-06 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US10519134B2 (en) * 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017197192A1 (en) * 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112020003946A2 (pt) 2017-08-29 2020-09-08 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos
ES2952332T3 (es) 2017-08-29 2023-10-30 H Lundbeck As Compuestos espirocíclicos y sus métodos de preparación y uso

Also Published As

Publication number Publication date
DOP2020000040A (es) 2020-08-31
CR20200088A (es) 2020-04-08
SG11202000984YA (en) 2020-03-30
EP3675848A4 (en) 2021-03-10
IL272578A (en) 2020-03-31
RU2020107039A (ru) 2021-09-30
ECSP20013332A (es) 2020-04-22
AU2018326497A1 (en) 2020-02-20
EP3675848B1 (en) 2022-03-23
CL2020000463A1 (es) 2020-07-10
MA50045A (fr) 2020-07-08
JP2020532547A (ja) 2020-11-12
PH12020500371A1 (en) 2020-12-07
CO2020001715A2 (es) 2020-02-28
KR20200046053A (ko) 2020-05-06
EP3675848A1 (en) 2020-07-08
EA202090296A1 (ru) 2020-08-03
MX2020002254A (es) 2020-07-20
PE20200665A1 (es) 2020-06-11
US11161856B2 (en) 2021-11-02
US20210214375A1 (en) 2021-07-15
CA3072926A1 (en) 2019-03-07
CN111032034A (zh) 2020-04-17
BR112020003946A2 (pt) 2020-09-08
WO2019046330A1 (en) 2019-03-07
ES2914363T3 (es) 2022-06-09
CN111032034B (zh) 2023-05-02
JP7177825B2 (ja) 2022-11-24

Similar Documents

Publication Publication Date Title
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12019501079A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
PH12019501102A1 (en) Magl inhibitors
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2017017119A (es) Formulacion de alta concentracion.
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy